speb/financial-data huggingface dataset:
CBIO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 116641000.00
CBIO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 112641000.00
CBIO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
CBIO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
CBIO balance_sheet (quarterly, 2025-09-30) — Total Assets: 138269000.00
CBIO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 116641000.00
CBIO balance_sheet (quarterly, 2025-09-30) — Total Debt: 1741000.00
CBIO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 116641000.00
CBIO income_statement (quarterly, 2025-09-30) — Total Expenses: 25885000.00
CBIO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 21628000.00
CBIO balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 3706000.00
CBIO balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 1324000.00
CBIO income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -25885000.00
CBIO balance_sheet (quarterly, 2025-09-30) — Working Capital: 114259000.00
CBIO income_statement (annual, 2025-12-31) — +Operating Expense: 163476000.00
CBIO income_statement (quarterly, 2025-12-31) — +Operating Expense: 102336000.00
CBIO income_statement (annual, 2025-12-31) — +Total Revenue: 10844000.00
CBIO income_statement (quarterly, 2025-12-31) — +Total Revenue: 10844000.00
CBIO balance_sheet (annual, 2025-12-31) — Accounts Payable: 9997000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 9997000.00
CBIO balance_sheet (annual, 2025-12-31) — Accounts Receivable: 18000000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 18000000.00
CBIO balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 370793000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 370793000.00
CBIO income_statement (annual, 2025-12-31) — Basic Average Shares: 10413649.00
CBIO income_statement (quarterly, 2025-12-31) — Basic Average Shares: 20170651.00
CBIO income_statement (annual, 2025-12-31) — Basic EPS: -12.81
CBIO income_statement (quarterly, 2025-12-31) — Basic EPS: -4.01
CBIO cash_flow (annual, 2025-12-31) — Beginning Cash Position: 34766000.00
CBIO cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 133372000.00
CBIO cash_flow (annual, 2025-12-31) — Capital Expenditure: -72919000.00
CBIO cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -72193000.00
CBIO balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 1644000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 1644000.00
CBIO balance_sheet (annual, 2025-12-31) — Capital Stock: 4028000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Capital Stock: 4028000.00
CBIO balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 213192000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 213192000.00
CBIO balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 213192000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 213192000.00
CBIO balance_sheet (annual, 2025-12-31) — Cash Financial: 213192000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Cash Financial: 213192000.00
CBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 322984000.00
CBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 178860000.00
CBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -72919000.00
CBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -72193000.00
CBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -71532000.00
CBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -26740000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Account Payable: 2081000.00
CBIO cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 1024000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 5363000.00
CBIO cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: -1059000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: 4963000.00
CBIO cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: 4903000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 4318000.00
CBIO cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 4193000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Payable: -5000000.00
CBIO cash_flow (quarterly, 2025-12-31) — Change In Payable: -5109000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 363000.00
CBIO cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -6168000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -5015000.00
CBIO cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -4165000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Receivables: -18000000.00
CBIO cash_flow (annual, 2025-12-31) — Change In Working Capital: -13371000.00
CBIO cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -19237000.00
CBIO cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -18000000.00
CBIO cash_flow (annual, 2025-12-31) — Changes In Cash: 178533000.00
CBIO cash_flow (quarterly, 2025-12-31) — Changes In Cash: 79927000.00
CBIO balance_sheet (annual, 2025-12-31) — Common Stock: 28000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Common Stock: 28000.00
CBIO balance_sheet (annual, 2025-12-31) — Common Stock Equity: 199012000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 199012000.00
CBIO cash_flow (annual, 2025-12-31) — Common Stock Issuance: 321887000.00
CBIO cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 178860000.00
CBIO cash_flow (annual, 2025-12-31) — Common Stock Payments: -177000.00
CBIO balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 3223000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 3223000.00
CBIO balance_sheet (annual, 2025-12-31) — Current Assets: 236655000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Current Assets: 236655000.00
CBIO balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 435000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 435000.00
CBIO balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 435000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 435000.00
CBIO balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 4156000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 4156000.00
CBIO balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 4156000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 4156000.00
CBIO balance_sheet (annual, 2025-12-31) — Current Liabilities: 36072000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 36072000.00
CBIO cash_flow (annual, 2025-12-31) — Depreciation: 84000.00
CBIO cash_flow (quarterly, 2025-12-31) — Depreciation: 54000.00
CBIO cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 84000.00
CBIO cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 54000.00
CBIO cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 84000.00
CBIO cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 54000.00
CBIO income_statement (annual, 2025-12-31) — Diluted Average Shares: 10413649.00
CBIO income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 20170651.00
CBIO income_statement (annual, 2025-12-31) — Diluted EPS: -12.81
CBIO income_statement (quarterly, 2025-12-31) — Diluted EPS: -4.01
CBIO income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -153942000.00
CBIO income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -92397000.00
CBIO balance_sheet (annual, 2025-12-31) — Dueto Related Parties Current: 140000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Dueto Related Parties Current: 140000.00
CBIO income_statement (annual, 2025-12-31) — EBIT: -149757000.00
CBIO income_statement (quarterly, 2025-12-31) — EBIT: -90397000.00
CBIO income_statement (annual, 2025-12-31) — EBITDA: -149673000.00
CBIO income_statement (quarterly, 2025-12-31) — EBITDA: -90343000.00
CBIO cash_flow (annual, 2025-12-31) — End Cash Position: 213299000.00
CBIO cash_flow (quarterly, 2025-12-31) — End Cash Position: 213299000.00
CBIO cash_flow (annual, 2025-12-31) — Financing Cash Flow: 322984000.00
CBIO cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 178860000.00
CBIO cash_flow (annual, 2025-12-31) — Free Cash Flow: -144451000.00
CBIO cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -98933000.00
CBIO income_statement (annual, 2025-12-31) — General And Administrative Expense: 25390000.00
CBIO income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 7309000.00
CBIO balance_sheet (annual, 2025-12-31) — Gross PPE: 2315000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Gross PPE: 2315000.00
CBIO income_statement (annual, 2025-12-31) — Interest Expense: 2185000.00
CBIO income_statement (quarterly, 2025-12-31) — Interest Expense: 0.00
CBIO income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 2185000.00
CBIO income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 0.00
CBIO income_statement (annual, 2025-12-31) — Interest Income: 2875000.00
CBIO income_statement (quarterly, 2025-12-31) — Interest Income: 1095000.00
CBIO income_statement (annual, 2025-12-31) — Interest Income Non Operating: 2875000.00
CBIO income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 1095000.00
CBIO balance_sheet (annual, 2025-12-31) — Interest Payable: 0.00
CBIO balance_sheet (quarterly, 2025-12-31) — Interest Payable: 0.00
CBIO balance_sheet (annual, 2025-12-31) — Invested Capital: 199012000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Invested Capital: 199012000.00
CBIO cash_flow (annual, 2025-12-31) — Investing Cash Flow: -72919000.00
CBIO cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -72193000.00
CBIO cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 321887000.00
CBIO cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 178860000.00
CBIO cash_flow (annual, 2025-12-31) — Issuance Of Debt: 0.00
CBIO balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 1209000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 1209000.00
CBIO balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1209000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1209000.00
CBIO cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 0.00
CBIO cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 321710000.00
CBIO cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 178683000.00
CBIO income_statement (annual, 2025-12-31) — Net Income: -153942000.00
CBIO income_statement (quarterly, 2025-12-31) — Net Income: -92397000.00
CBIO income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -153942000.00
CBIO income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -92397000.00
CBIO income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -153942000.00
CBIO income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -92397000.00
CBIO income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -153942000.00
CBIO income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -92397000.00
CBIO income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -153942000.00
CBIO income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -92397000.00
CBIO cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -153942000.00
CBIO cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -92397000.00
CBIO income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -153942000.00
CBIO income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -92397000.00
CBIO cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -72000000.00
CBIO income_statement (annual, 2025-12-31) — Net Interest Income: 690000.00
CBIO income_statement (quarterly, 2025-12-31) — Net Interest Income: 1095000.00
CBIO cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 0.00
CBIO cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 0.00
CBIO income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 690000.00
CBIO income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 1095000.00
CBIO cash_flow (annual, 2025-12-31) — Net Other Financing Charges: 1269000.00
CBIO cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: 0.00
CBIO balance_sheet (annual, 2025-12-31) — Net PPE: 2315000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Net PPE: 2315000.00
CBIO cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -919000.00
CBIO cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -193000.00
CBIO cash_flow (annual, 2025-12-31) — Net Preferred Stock Issuance: 0.00
CBIO balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 203012000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 203012000.00
CBIO income_statement (annual, 2025-12-31) — Normalized EBITDA: -149673000.00
CBIO income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -90343000.00
CBIO income_statement (annual, 2025-12-31) — Normalized Income: -153942000.00
CBIO income_statement (quarterly, 2025-12-31) — Normalized Income: -92397000.00
CBIO cash_flow (annual, 2025-12-31) — Operating Cash Flow: -71532000.00
CBIO cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -26740000.00
CBIO income_statement (annual, 2025-12-31) — Operating Income: -152632000.00
CBIO income_statement (quarterly, 2025-12-31) — Operating Income: -91492000.00
CBIO income_statement (annual, 2025-12-31) — Operating Revenue: 10844000.00
CBIO income_statement (quarterly, 2025-12-31) — Operating Revenue: 10844000.00
CBIO balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 30446767.00
CBIO balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 30446767.00
CBIO balance_sheet (annual, 2025-12-31) — Other Current Assets: 1278000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 1278000.00
CBIO balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 5000000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 5000000.00
CBIO income_statement (annual, 2025-12-31) — Other Gand A: 10833000.00
CBIO income_statement (quarterly, 2025-12-31) — Other Gand A: 3269000.00
CBIO cash_flow (annual, 2025-12-31) — Other Non Cash Items: 82397000.00
CBIO cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 80095000.00
CBIO balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 1323000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 1323000.00
CBIO balance_sheet (annual, 2025-12-31) — Other Properties: 2315000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Other Properties: 2315000.00
CBIO balance_sheet (annual, 2025-12-31) — Payables: 18137000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Payables: 18137000.00
CBIO balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 21360000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 21360000.00
CBIO balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 5121000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 5121000.00
CBIO balance_sheet (annual, 2025-12-31) — Preferred Securities Outside Stock Equity: 0.00
CBIO balance_sheet (quarterly, 2025-12-31) — Preferred Securities Outside Stock Equity: 0.00
CBIO balance_sheet (annual, 2025-12-31) — Preferred Stock: 4000000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 4000000.00
CBIO balance_sheet (annual, 2025-12-31) — Preferred Stock Equity: 4000000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Preferred Stock Equity: 4000000.00
CBIO cash_flow (annual, 2025-12-31) — Preferred Stock Issuance: 0.00
CBIO balance_sheet (annual, 2025-12-31) — Prepaid Assets: 4185000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 4185000.00
CBIO income_statement (annual, 2025-12-31) — Pretax Income: -151942000.00
CBIO income_statement (quarterly, 2025-12-31) — Pretax Income: -90397000.00
CBIO cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 5000.00
CBIO cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 177000.00
CBIO cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -72000000.00
CBIO cash_flow (annual, 2025-12-31) — Purchase Of PPE: -919000.00
CBIO cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -193000.00
CBIO balance_sheet (annual, 2025-12-31) — Receivables: 18000000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Receivables: 18000000.00
CBIO income_statement (annual, 2025-12-31) — Reconciled Depreciation: 84000.00
CBIO income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 54000.00
CBIO cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -177000.00
CBIO income_statement (annual, 2025-12-31) — Research And Development: 138086000.00
CBIO income_statement (quarterly, 2025-12-31) — Research And Development: 95027000.00
CBIO balance_sheet (annual, 2025-12-31) — Retained Earnings: -171809000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -171809000.00
CBIO income_statement (annual, 2025-12-31) — Salaries And Wages: 14557000.00
CBIO income_statement (quarterly, 2025-12-31) — Salaries And Wages: 4040000.00
CBIO income_statement (annual, 2025-12-31) — Selling General And Administration: 25390000.00
CBIO income_statement (quarterly, 2025-12-31) — Selling General And Administration: 7309000.00
CBIO balance_sheet (annual, 2025-12-31) — Share Issued: 30446767.00
CBIO balance_sheet (quarterly, 2025-12-31) — Share Issued: 30446767.00
CBIO cash_flow (annual, 2025-12-31) — Stock Based Compensation: 13300000.00
CBIO cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 4745000.00
CBIO balance_sheet (annual, 2025-12-31) — Stockholders Equity: 203012000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 203012000.00
CBIO balance_sheet (annual, 2025-12-31) — Tangible Book Value: 199012000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 199012000.00
CBIO income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
CBIO income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
CBIO income_statement (annual, 2025-12-31) — Tax Provision: 2000000.00
CBIO income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.21
CBIO income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
CBIO balance_sheet (annual, 2025-12-31) — Total Assets: 240293000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Total Assets: 240293000.00
CBIO balance_sheet (annual, 2025-12-31) — Total Capitalization: 203012000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 203012000.00
CBIO balance_sheet (annual, 2025-12-31) — Total Debt: 1644000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Total Debt: 1644000.00
CBIO balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 203012000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 203012000.00
CBIO income_statement (annual, 2025-12-31) — Total Expenses: 163476000.00
CBIO income_statement (quarterly, 2025-12-31) — Total Expenses: 102336000.00
CBIO balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 37281000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 37281000.00
CBIO balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 3638000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 3638000.00
CBIO balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1209000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1209000.00
CBIO income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -152632000.00
CBIO income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -91492000.00
CBIO balance_sheet (annual, 2025-12-31) — Total Tax Payable: 8000000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 8000000.00
CBIO balance_sheet (annual, 2025-12-31) — Working Capital: 200583000.00
CBIO balance_sheet (quarterly, 2025-12-31) — Working Capital: 200583000.00
CBIO income_statement (quarterly, 2026-03-31) — +Operating Expense: 25768000.00
CBIO income_statement (quarterly, 2026-03-31) — +Total Revenue: 1039000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1190000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 0.00
CBIO balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 374911000.00
CBIO income_statement (quarterly, 2026-03-31) — Basic Average Shares: 30397886.00
CBIO income_statement (quarterly, 2026-03-31) — Basic EPS: -0.70
CBIO cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 213299000.00
CBIO cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -8147000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 1543000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Capital Stock: 4028000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 189163000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 189163000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Cash Financial: 189163000.00
CBIO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -6945000.00
CBIO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -8147000.00
CBIO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -8937000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -2312000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -3456000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -101000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -982000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Payable: -2452000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -5908000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -937000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Receivables: 18000000.00
CBIO cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 10072000.00
CBIO cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 18000000.00
CBIO cash_flow (quarterly, 2026-03-31) — Changes In Cash: -24029000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Common Stock: 28000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 179847000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 2617000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Current Assets: 195563000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 453000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 453000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 3117000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 3117000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 14193000.00
CBIO cash_flow (quarterly, 2026-03-31) — Depreciation: 64000.00
CBIO cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 64000.00
CBIO cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 64000.00
CBIO income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 30397886.00
CBIO income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.70
CBIO income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -23283000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Dueto Related Parties Current: 0.00
CBIO income_statement (quarterly, 2026-03-31) — EBIT: -23283000.00
CBIO income_statement (quarterly, 2026-03-31) — EBITDA: -23219000.00
CBIO cash_flow (quarterly, 2026-03-31) — End Cash Position: 189270000.00
CBIO cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -6945000.00
CBIO cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -17084000.00
CBIO income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 7865000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Gross PPE: 2301000.00
CBIO income_statement (quarterly, 2026-03-31) — Interest Expense: 0.00
CBIO income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 0.00
CBIO income_statement (quarterly, 2026-03-31) — Interest Income: 1446000.00
CBIO income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 1446000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Invested Capital: 179847000.00
CBIO cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -8147000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 1090000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 1090000.00
CBIO income_statement (quarterly, 2026-03-31) — Net Income: -23283000.00
CBIO income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -23283000.00
CBIO income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -23283000.00
CBIO income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -23283000.00
CBIO income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -23283000.00
CBIO cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -23283000.00
CBIO income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -23283000.00
CBIO cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: -8000000.00
CBIO income_statement (quarterly, 2026-03-31) — Net Interest Income: 1446000.00
CBIO income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 1446000.00
CBIO cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -6945000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Net PPE: 2301000.00
CBIO cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -147000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 183847000.00
CBIO income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -23219000.00
CBIO income_statement (quarterly, 2026-03-31) — Normalized Income: -23283000.00
CBIO cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -8937000.00
CBIO income_statement (quarterly, 2026-03-31) — Operating Income: -24729000.00
CBIO income_statement (quarterly, 2026-03-31) — Operating Revenue: 1039000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 27574825.00
CBIO balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 1373000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 5000000.00
CBIO income_statement (quarterly, 2026-03-31) — Other Gand A: 3386000.00
CBIO cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 97000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 1266000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Other Properties: 2301000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Payables: 1190000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 3807000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 1816000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 4000000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Preferred Stock Equity: 4000000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 5027000.00
CBIO income_statement (quarterly, 2026-03-31) — Pretax Income: -23283000.00
CBIO cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 0.00
CBIO cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: -8000000.00
CBIO cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -147000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Receivables: 0.00
CBIO income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 64000.00
CBIO income_statement (quarterly, 2026-03-31) — Research And Development: 17903000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -195092000.00
CBIO income_statement (quarterly, 2026-03-31) — Salaries And Wages: 4479000.00
CBIO income_statement (quarterly, 2026-03-31) — Selling General And Administration: 7865000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Share Issued: 27574825.00
CBIO cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 4113000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 183847000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 179847000.00
CBIO income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
CBIO income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
CBIO balance_sheet (quarterly, 2026-03-31) — Total Assets: 199130000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 183847000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Total Debt: 1543000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 183847000.00
CBIO income_statement (quarterly, 2026-03-31) — Total Expenses: 25768000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 15283000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 3567000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 1090000.00
CBIO income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -24729000.00
CBIO balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 0.00
CBIO balance_sheet (quarterly, 2026-03-31) — Working Capital: 181370000.00
CBIT.V income_statement (annual, 2023-12-31) — +Operating Expense: 319633.00
CBIT.V income_statement (annual, 2023-12-31) — +Total Revenue: 14952858.00
CBIT.V balance_sheet (annual, 2023-12-31) — Accounts Payable: 774266.00
CBIT.V balance_sheet (annual, 2023-12-31) — Accounts Receivable: 1336413.00
CBIT.V balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -509062.00
CBIT.V cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Assets Held For Sale Current: 0.00
CBIT.V income_statement (annual, 2023-12-31) — Basic Average Shares: 243767364.00
CBIT.V income_statement (annual, 2023-12-31) — Basic EPS: 0.01
CBIT.V cash_flow (annual, 2023-12-31) — Beginning Cash Position: 295255.00
CBIT.V cash_flow (annual, 2023-12-31) — Capital Expenditure: -2961312.00
CBIT.V balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 715896.00
CBIT.V balance_sheet (annual, 2023-12-31) — Capital Stock: 1278.00
CBIT.V balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 122188.00
CBIT.V balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 122188.00
CBIT.V cash_flow (annual, 2023-12-31) — Cash Dividends Paid: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 915824.00
CBIT.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -3435303.00
CBIT.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 2341446.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Account Payable: 206400.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -49573.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: 2236036.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -156091.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Payable: 206400.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 206400.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -1968856.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Receivables: -1239354.00
CBIT.V cash_flow (annual, 2023-12-31) — Change In Working Capital: -971438.00
CBIT.V cash_flow (annual, 2023-12-31) — Changes In Cash: -178033.00
CBIT.V balance_sheet (annual, 2023-12-31) — Common Stock: 1278.00
CBIT.V balance_sheet (annual, 2023-12-31) — Common Stock Equity: 2292129.00
CBIT.V balance_sheet (annual, 2023-12-31) — Construction In Progress: 539862.00
CBIT.V income_statement (annual, 2023-12-31) — Cost Of Revenue: 11517370.00
CBIT.V balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 865.00
CBIT.V balance_sheet (annual, 2023-12-31) — Current Assets: 1949086.00
CBIT.V balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 34487.00
CBIT.V balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 34487.00
CBIT.V balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 318565.00
CBIT.V balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 318565.00
CBIT.V balance_sheet (annual, 2023-12-31) — Current Liabilities: 3714005.00
CBIT.V cash_flow (annual, 2023-12-31) — Deferred Income Tax: 34984.00
CBIT.V cash_flow (annual, 2023-12-31) — Deferred Tax: 34984.00
CBIT.V cash_flow (annual, 2023-12-31) — Depreciation: 565023.00
CBIT.V cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 565023.00
CBIT.V cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 565023.00
CBIT.V income_statement (annual, 2023-12-31) — Diluted Average Shares: 243767364.00
CBIT.V income_statement (annual, 2023-12-31) — Diluted EPS: 0.01
CBIT.V income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 2586291.00
CBIT.V balance_sheet (annual, 2023-12-31) — Dueto Related Parties Current: 2266378.00
CBIT.V income_statement (annual, 2023-12-31) — EBIT: 3144323.00
CBIT.V income_statement (annual, 2023-12-31) — EBITDA: 3709346.00
CBIT.V cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 4966.00
CBIT.V cash_flow (annual, 2023-12-31) — End Cash Position: 122188.00
CBIT.V balance_sheet (annual, 2023-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Financing Cash Flow: 915824.00
CBIT.V cash_flow (annual, 2023-12-31) — Free Cash Flow: -619866.00
CBIT.V balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -54407.00
CBIT.V income_statement (annual, 2023-12-31) — General And Administrative Expense: 410669.00
CBIT.V balance_sheet (annual, 2023-12-31) — Goodwill: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Gross PPE: 5246024.00
CBIT.V income_statement (annual, 2023-12-31) — Gross Profit: 3435488.00
CBIT.V balance_sheet (annual, 2023-12-31) — Income Tax Payable: 37493.00
CBIT.V income_statement (annual, 2023-12-31) — Interest Expense: 117288.00
CBIT.V income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 117288.00
CBIT.V cash_flow (annual, 2023-12-31) — Interest Paid Cff: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Interest Received Cfo: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Invested Capital: 2292129.00
CBIT.V cash_flow (annual, 2023-12-31) — Investing Cash Flow: -3435303.00
CBIT.V balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Investments And Advances: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Land And Improvements: 136658.00
CBIT.V balance_sheet (annual, 2023-12-31) — Leases: 737903.00
CBIT.V balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 681409.00
CBIT.V balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 681409.00
CBIT.V cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -142197.00
CBIT.V balance_sheet (annual, 2023-12-31) — Minority Interest: 0.00
CBIT.V income_statement (annual, 2023-12-31) — Minority Interests: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Net Foreign Currency Exchange Gain Loss: 0.00
CBIT.V income_statement (annual, 2023-12-31) — Net Income: 2586291.00
CBIT.V income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 2586291.00
CBIT.V income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 2995011.00
CBIT.V income_statement (annual, 2023-12-31) — Net Income Discontinuous Operations: -408720.00
CBIT.V income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 2586291.00
CBIT.V income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 2995011.00
CBIT.V cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 2586291.00
CBIT.V income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 2586291.00
CBIT.V income_statement (annual, 2023-12-31) — Net Interest Income: -117288.00
CBIT.V cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -142197.00
CBIT.V cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -142197.00
CBIT.V income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -117288.00
CBIT.V cash_flow (annual, 2023-12-31) — Net Other Financing Charges: 1058021.00
CBIT.V cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -473991.00
CBIT.V balance_sheet (annual, 2023-12-31) — Net PPE: 4736962.00
CBIT.V cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -2961312.00
CBIT.V balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 2292129.00
CBIT.V balance_sheet (annual, 2023-12-31) — Non Current Prepaid Assets: 2147668.00
CBIT.V income_statement (annual, 2023-12-31) — Normalized EBITDA: 3709346.00
CBIT.V income_statement (annual, 2023-12-31) — Normalized Income: 2995011.00
CBIT.V cash_flow (annual, 2023-12-31) — Operating Cash Flow: 2341446.00
CBIT.V income_statement (annual, 2023-12-31) — Operating Income: 3115855.00
CBIT.V income_statement (annual, 2023-12-31) — Operating Revenue: 14952858.00
CBIT.V balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 243767364.00
CBIT.V balance_sheet (annual, 2023-12-31) — Other Current Assets: 54027.00
CBIT.V balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 281951.00
CBIT.V balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -54407.00
CBIT.V income_statement (annual, 2023-12-31) — Other Gand A: 410669.00
CBIT.V income_statement (annual, 2023-12-31) — Other Income Expense: 28468.00
CBIT.V balance_sheet (annual, 2023-12-31) — Other Investments: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Other Non Cash Items: 117288.00
CBIT.V balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 956496.00
CBIT.V balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 3102669.00
CBIT.V income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 28468.00
CBIT.V income_statement (annual, 2023-12-31) — Other Operating Expenses: -91036.00
CBIT.V balance_sheet (annual, 2023-12-31) — Other Properties: 3051267.00
CBIT.V balance_sheet (annual, 2023-12-31) — Payables: 3078137.00
CBIT.V balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 3079002.00
CBIT.V balance_sheet (annual, 2023-12-31) — Prepaid Assets: 436458.00
CBIT.V income_statement (annual, 2023-12-31) — Pretax Income: 3027035.00
CBIT.V balance_sheet (annual, 2023-12-31) — Properties: 780334.00
CBIT.V cash_flow (annual, 2023-12-31) — Purchase Of PPE: -2961312.00
CBIT.V balance_sheet (annual, 2023-12-31) — Receivables: 1336413.00
CBIT.V income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 11517370.00
CBIT.V income_statement (annual, 2023-12-31) — Reconciled Depreciation: 565023.00
CBIT.V cash_flow (annual, 2023-12-31) — Repayment Of Debt: -142197.00
CBIT.V income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Retained Earnings: 2345258.00
CBIT.V income_statement (annual, 2023-12-31) — Salaries And Wages: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Sale Of Business: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Sale Of Investment: 0.00
CBIT.V income_statement (annual, 2023-12-31) — Selling General And Administration: 410669.00
CBIT.V balance_sheet (annual, 2023-12-31) — Share Issued: 243767364.00
CBIT.V income_statement (annual, 2023-12-31) — Special Income Charges: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Stock Based Compensation: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Stockholders Equity: 2292129.00
CBIT.V balance_sheet (annual, 2023-12-31) — Tangible Book Value: 2292129.00
CBIT.V income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
CBIT.V income_statement (annual, 2023-12-31) — Tax Provision: 32024.00
CBIT.V income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.01
CBIT.V cash_flow (annual, 2023-12-31) — Taxes Refund Paid: 0.00
CBIT.V balance_sheet (annual, 2023-12-31) — Total Assets: 9790212.00
CBIT.V balance_sheet (annual, 2023-12-31) — Total Capitalization: 2292129.00
CBIT.V balance_sheet (annual, 2023-12-31) — Total Debt: 715896.00
CBIT.V balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 2292129.00
CBIT.V income_statement (annual, 2023-12-31) — Total Expenses: 11837003.00
CBIT.V balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 7498083.00
CBIT.V balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 7841126.00
CBIT.V balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 3784078.00
CBIT.V income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 3125153.00
CBIT.V balance_sheet (annual, 2023-12-31) — Total Tax Payable: 37493.00
CBIT.V income_statement (annual, 2023-12-31) — Total Unusual Items: 0.00
CBIT.V income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 0.00
CBIT.V cash_flow (annual, 2023-12-31) — Unrealized Gain Loss On Investment Securities: 9298.00
CBIT.V balance_sheet (annual, 2023-12-31) — Working Capital: -1764919.00
CBIT.V income_statement (quarterly, 2024-09-30) — +Operating Expense: 1331093.00
CBIT.V income_statement (quarterly, 2024-09-30) — +Total Revenue: 5857825.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 1833460.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 128385.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Accumulated Depreciation: -2233822.00
CBIT.V income_statement (quarterly, 2024-09-30) — Basic Average Shares: 806407195.00
CBIT.V income_statement (quarterly, 2024-09-30) — Basic EPS: -0.01
CBIT.V cash_flow (quarterly, 2024-09-30) — Beginning Cash Position: 333289.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 2337581.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Capital Stock: 22984416.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 669499.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 669499.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Cash Dividends Paid: 0.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Cash Flow From Continuing Financing Activities: 2008911.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Cash Flow From Continuing Investing Activities: 1881031.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Cash Flow From Continuing Operating Activities: -3521915.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Account Payable: 152508.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Other Current Assets: -1336540.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Other Current Liabilities: -1193935.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Other Working Capital: -2762072.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Payable: 157736.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Payables And Accrued Expense: 157736.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Prepaid Assets: 774865.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Receivables: 273483.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Change In Working Capital: -4084252.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Changes In Cash: 368027.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Common Stock: 22984416.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 27362375.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 496156.00
CBIT.V income_statement (quarterly, 2024-09-30) — Cost Of Revenue: 5097300.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Current Accrued Expenses: 1841409.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Current Assets: 7831174.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 1172360.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 1172360.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Current Deferred Liabilities: 26393.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Current Deferred Revenue: 26393.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 7699500.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Current Provisions: 30373.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Depreciation: 1415132.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Depreciation Amortization Depletion: 1415132.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Depreciation And Amortization: 1415132.00
CBIT.V income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 806407195.00
CBIT.V income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.01
CBIT.V income_statement (quarterly, 2024-09-30) — Diluted NI Availto Com Stockholders: -4109271.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Duefrom Related Parties Current: 20795.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Dueto Related Parties Current: 12882.00
CBIT.V income_statement (quarterly, 2024-09-30) — EBIT: -2228334.00
CBIT.V income_statement (quarterly, 2024-09-30) — EBITDA: -813202.00
CBIT.V income_statement (quarterly, 2024-09-30) — Earnings From Equity Interest: -331788.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Effect Of Exchange Rate Changes: -31817.00
CBIT.V cash_flow (quarterly, 2024-09-30) — End Cash Position: 669499.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 512156.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Financing Cash Flow: 2008911.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Free Cash Flow: -3521915.00
CBIT.V income_statement (quarterly, 2024-09-30) — Gain On Sale Of Business: 0.00
CBIT.V income_statement (quarterly, 2024-09-30) — Gain On Sale Of Security: -984137.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Gains Losses Not Affecting Retained Earnings: 4407736.00
CBIT.V income_statement (quarterly, 2024-09-30) — General And Administrative Expense: 1114498.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Goodwill: 25128781.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 25128781.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Gross PPE: 13048714.00
CBIT.V income_statement (quarterly, 2024-09-30) — Gross Profit: 760525.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Income Tax Payable: 2010269.00
CBIT.V income_statement (quarterly, 2024-09-30) — Interest Expense: 1521812.00
CBIT.V income_statement (quarterly, 2024-09-30) — Interest Expense Non Operating: 1521812.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Interest Paid Cff: -50171.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Inventory: 933928.00
CBIT.V balance_sheet (quarterly, 2024-09-30) — Invested Capital: 32321539.00
CBIT.V cash_flow (quarterly, 2024-09-30) — Investing Cash Flow: 1881031.00